X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): COM902,COM701
Therapeutic Area: Oncology Product Name: COM902
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2021
Details:
Peer reviewed data demonstrate synergistic effect of anti-TIGIT antibody, COM902, with PVRIG and PD-1 blockade for the treatment of cancer. COM902 is currently being studied as monotherapy in a Phase 1 trial of patients with advanced malignancies.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TIGITxPD1 fusion protein
Therapeutic Area: Oncology Product Name: DSP502
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Kahr Medical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 01, 2021
Details:
Under the agreement, Thomas Jefferson University is granting KAHR an exclusive license to develop and commercialize multiple new drug candidates including DSP502, a TIGITxPD1 fusion protein, and DSP216, a LILRB2xSIRPa fusion protein for immuno-oncology.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Aminolevulinic Acid HCl
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: SonALAsense
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 14, 2020
Details:
The collaboration aims at conducting a first-in-human clinical trial in rGBM using SonALAsense's innovative Phase 0 approach to rapidly assess safety, and biological and clinical efficacy of aminolevulinic acid (ALA SDT).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Opaganib,Upamostat
Therapeutic Area: Oncology Product Name: Yeliva
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2020
Details:
Notice of Allowance received for combination of RedHill’s novel orally administered investigational drugs, opaganib and RHB-107, for treatment of solid tumor cancers; patent expected to extend IP protection until 2036.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
